Systematic review and meta-analysis of Statins-Fibrates therapy in diabetic dyslipidemia patients

Table 1 Basic characteristics of included studies

Ref.	Type	Number(T/C1/C2)	Age (mean)(T/C1/C2)	Men (%)	Treatment	Contral 1	Contral 2	Duration(mo)
Athyros et al[19] 2002	RCT	40/40/40	58/57/58	56.7	A + Fe	A	Fe	6
Durrington et al[22] 2004	RCT	115/53/48	60/60/60	53.0	R + Fe	R	Fe	6
Rosenson et al[21] 2011	RCT	177/173/123	60/58/58	41.4	R + FA	R	FA	3
Derosa et al[18] 2004	RCT	25/23/0	61/59/0	50.0	F + Fe	F		6
Farnier et al[16] 2011	RCT	145/146/0	56/57/0	48.1	P + Fe	S		3
Hamilton et al[17] 2010	RCT	15/0/15	63/0/63	86.7	A/S/P/R + Fe		Fe	3
Ginsberg et al[20] 2010	RCT	2765/2753/0	62/62/0	69.3	S + Fe	S		56.4
Gavish et al[13] 2000	CCT	146/100/48	59/58/60	57.4	S + B	S	B	21
Constantinides et al[15] 2012	CCT	14/14/14	> 18/> 18/> 18	100	S + B	S	B	2
Klempfner et al[14] 2014	CSS	225/2838/0	60/65/0	71.0	A/S/P/C/F + B		B	12

RCT: Randomized controlled trial; CCT: Controlled clinical trial; CSS: Cross-sectional study; T/C1/C2: Treatment/Control 1/Control 2; S: Simvastatin; B: Bezafibrate; F: Fluvastatin; Fe: Fenofibrate; A: Atorvastatin; P: Pravastatin; R: Rosuvastatin; C: Cerivastatin; FA: Fenofibric acid.